NCT02386397 2026-03-12
BREGO
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1/2 Completed
Clinical Trials
18 trialsNCT07137390 2026-03-11
A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT03828799 2026-02-27
FOLFIRINOX-R
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1/2 Completed
NCT05672316 2026-01-28
Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy
City of Hope Medical Center
Phase 1/2 Active not recruiting
NCT04781192 2026-01-23
The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers
University of Kansas Medical Center
Phase 1/2 Active not recruiting
NCT03377361 2025-12-03
CheckMate 9N9
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04660812 2025-10-20
ARC-9
Arcus Biosciences, Inc.
Phase 1/2 Completed
NCT03657641 2025-07-04
Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer
University of Southern California
Phase 1/2 Active not recruiting
NCT03563157 2024-12-11
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT04170556 2024-09-03
GOING
Fundacion Clinic per a la Recerca Biomédica
Phase 1/2 Completed
NCT02024607 2023-11-15
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
Sumitomo Pharma America, Inc.
Phase 1/2 Completed
NCT03555149 2023-11-07
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
Hoffmann-La Roche
Phase 1/2 Terminated
NCT03475953 2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2 Unknown
NCT05426811 2022-06-29
Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients
China Medical University, China
Phase 1/2 Unknown
NCT03946917 2020-05-12
JS001 Combined With Regorafenib in Patients With Advanced Colorectal Cancer
Sun Yat-sen University
Phase 1/2 Unknown
NCT02406170 2019-10-22
REPEAT
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 1/2 Completed
NCT04008511 2019-07-05
Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer
China Medical University, China
Phase 1/2 Unknown